Table 2.
The effects of EGCG on liver and kidney functions in obese subjects.
| Variables | Placebo (n = 15) |
EGCG (n = 15) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline |
Week 8 |
(t values/NP, P values) | Baseline |
Week 8 |
(t values/NP, P values) | |||||||||
| P25 | Med | P75 | P25 | Med | P75 | P25 | Med | P75 | P25 | Med | P75 | |||
| Total bilirubin (mg/dL) | 0.35 | 0.40 | 0.70 | 0.32 | 0.39 | 0.51 | (NP, 0.589) | 0.32 | 0.48 | 0.60 | 0.30 | 0.45 | 0.59 | (1.70, 0.112) |
| Direct bilirubin (mg/dL) | 0.11 | 0.14 | 0.17 | 0.10 | 0.13 | 0.20 | (NP, 0.648) | 0.12 | 0.17 | 0.20 | 0.12 | 0.15 | 0.21 | (NP, 0.150) |
| AST (U/L) | 14.00 | 17.00 | 22.00 | 15.00 | 20.00 | 27.00 | (–0.99, 0.336) | 15.00 | 22.00 | 26.00 | 14.00 | 21.00 | 26.00 | (0.21, 0.840) |
| ALT (U/L) | 14.00 | 17.50 | 24.25 | 15.00 | 18.00 | 29.00 | (NP, 0.342) | 16.00 | 22.00 | 44.00 | 14.00 | 30.00 | 45.00 | (–0.72, 0.483) |
| BUN (mg/dL) | 8.60 | 10.70 | 12.40 | 9.00 | 10.70 | 14.60 | (–0.80, 0.435) | 9.60 | 12.10 | 15.60 | 9.80 | 12.90 | 15.40 | (–0.63, 0.535) |
| Creatinine (mg/dL) | 0.60 | 0.69 | 1.01 | 0.62 | 0.75 | 1.08 | (NP, 0.362) | 0.65 | 0.94 | 1.15 | 0.69 | 0.86 | 1.20 | (0.35, 0.730) |
| eGFR (mL/min) | 93.55 | 105.81 | 117.30 | 96.57 | 103.51 | 114.76 | (1.11, 0.285) | 87.47 | 98.63 | 114.36 | 78.92 | 103.03 | 114.36 | (–0.48, 0.640) |
EGCG: epigallocatechin gallate; NP: non-parametric test; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate.
The liver and kidney functions of obese human subjects supplemented with placebo or EGCG at baseline and week 8 including total bilirubin, direct bilirubin, AST, ALT, BUN, creatinine, and eGFR.